THE EFFICACY AND SAFETY OF CARMOLIS GEL IN THE COMBINATION THERAPY OF KNEE OSTEOARTHRITIS: RESULTS OF A MULTICENTER CLINICAL TRIAL

Osteoarthritis (OA) is one of the most common rheumatic diseases. Knee OA is particularly frequently encountered among all forms of OA, the prevalence of knee OA being about 25% in the general population. Despite multiple guidelines for the management of knee OA, which have been prepared by the European League Against Rheumatism (EULAR), the American College of Rheumatology (ACR), and the Osteoarthritis Research Society International (OARSI), many problems of its treatment policy remain to be solved. The same holds true for not only the symptomatic and disease-modifying effects of chondroprotectors, but also topical therapy options.

Objective: to evaluate the clinical efficacy and safety of Carmolis gel in patients with knee OA.

Subjects and methods.The trial included 280 patients with knee OA (a study group consisted of 190 patents; a control group comprised 90 patients). The mean age was 58.3±9.3 years in the study group and 59±10.5 years in the control group. The disease duration was 10.3±5.5 and 10.1±4.1 years, respectively. Carmolis gel was applied to the region of the most painful knee joint up to 4–5 times daily, followed by massage of this skin area. The treatment cycle lasted for 2 weeks. No therapy was performed in the control patients. The clinical efficacy was determined by the changes in joint pains at rest or on movement and palpation, according to a visual analogue scale (VAS), WOMAC questionnaire, the synovitis intensity (assessed by ultrasonography), patient and physician global assessments of disease activity (Likert scale), and the possibility of reducing the daily dosage of nonsteroidal anti-inflammatory drugs (NSAIDs). The onset the therapeutic effect of the gel and the duration of its action were recorded.

Results and discussion. The topical application of Carmolis gel caused a statistically significant reduction in joint pain at rest and on movement from 57.7±6.8 to 12±1.8 mm (р < 0.01) and from 52±5.3 to 17±2.7 mm, respectively (р<0.01). The WOMAC showed similar pain changes. In the study group, the WOMAC pain level averaged 210±20.5 mm at baseline and reduced to 101±12.8 mm after the treatment (p < 0.01).The control group also exhibited pain relief, but to a much lesser degree than did the study group. There were no statistically significant differences between the groups in motor and day-to-day activity changes. After treatment, the patients of both groups had reduction in the signs of synovitis; however, no differences were found between the groups. The dose of NSAIDs could be decreased in 99 (52.1%) of the 190 patients in the study group and only in 15 (16.6%) of the 90 patients in the control group (p<0.05). Carmolis gel was well tolerated. No adverse events were observed in 184 patients. Local cutaneous reactions and itch were noted in 6 (3.2%) patients; however, they were short-term and did not required drug discontinuation.

Conclusion. The findings suggest that the incorporation of Carmolis gel into the combination therapy of OA ensures a significant reduction in joint pain and allows the dose of NSAIDS to be decreased, making the treatment safer.

1. Brjsma JW, Berenbaum F, Lafeber FR. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115–26. doi: 10.1016/S0140-6736(11) 60243-2

2. Pereira D, Peleteiro B, Aromjo R, et al. The effect of osteoarthritis definition on prevalence and incidence osteoarthritis estimates: a systemic review. Osteoarthritis Cartilage. 2011;19(11):1270–85. doi: 10.1016/j.joca. 2011. 08.009

3. Pincus N. Clinical evidence for osteoarthritis as an inflammatory disease. Curr Rheumatol Rep. 2006;3(6):524–34. doi: 10.1007/s11926-001-0068-4

4. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74 (Review). doi: 10.1002/acr.21596

5. Bruyere O, Coopert C, Pelletier J-P, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):2523–63. doi: 10.1016/j.semarthrit 2014.05.014

6. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for international clinical studies including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–55. doi: 10.1136/ard. 2003. 011742

7. Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4–23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice ». Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2015;(1):4–23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23

8. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systemic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2012;18(4):476–99. doi: 10.1016/j.joca.2010.01.013

9. Насонов ЕЛ. Ревматология: клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 с. [Nasonov EL. Revmatologiya: klinicheskie rekomendatsii [Rheumatology: treatment guidelines]. Moscow: GEOTAR-Media; 2010. 752 p.].

10. Федина ТП, Гришаева ТП, Щекина ЕВ и др. Опыт клинического применения геля «Диклофенак Плюс» в комплексной терапии ревматических заболеваний. Русский медицинский журнал. 2004;12(20):1156–8 [Fedina TP, Grishaeva TP, Shchekina EV, et al. Experience of clinical application of the gel "Diclofenac Plus" in the treatment of rheumatic diseases. Russkii meditsinskii zhurnal. 2004;12(20):1156–8 (In Russ.)].

11. Денисов ЛН. Современные подходы к локальной терапии ревматических заболеваний. Consilium Medicum. Прил. Неврология/ревматология. 2013;(2):32–5 [Denisov LN. Modern approaches to local treatment of rheumatic diseases. Consilium Medicum. Suppl. Nevrologiya/revmatologiya. 2013;(2):32–5 (In Russ.)].

12. Денисов ЛН, Прозоровская ЗА, Иванова ОН и др. Повышает ли комбинация нестероидных противовоспалительных препаратов и ментола эффективность локальной терапии. Научно-практическая ревматология. 2006;(1):34–9 [Denisov LN, Prozorovskaya ZA, Ivanova ON, et al. Increases whether the combination of NSAIDs and menthol effectiveness of local therapy. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2006;(1):34–9 (In Russ.)].

13. Денисов ЛН, Прозоровская ЗА, Коган КМ и др. Опыт клинического применения геля «Дип Рилиф» и крема «Долгит» в локальной терапии ревматоидного артрита. Научно-практическая ревматология. 2006;(2):82–4 [Denisov LN, Prozorovskaya ZA, Kogan KM, et al. Experience of clinical application of the gel "Deep Relief" and cream "duty" in the local treatment of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2006;(2):82–4 (In Russ.)].

14. Цветкова ЕС, Денисов ЛН, Гукасян ДА, Шахраманова ЕЛ. Бальзам «Мерцана-Артровит согревающий»: эффективность и переносимость при остеоартрозе коленных суставов. Науч-но-практическая ревматология. 2007;(5):61–5 [Tsvetkova ES, Denisov LN, Gukasyan DA, Shahramanova EL. Balsam “Mercana-Artrovit warming” – efficacy and tolerability in knee osteoarthritis. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2007;(5):61–5 (In Russ.)].

15. Ананьева ЛП, Панасюк ЕЮ, Денисов ЛН и др. Боли в нижней части спины в практике ревматолога, локальная терапия Версатисом. Справочник поликлинического врача. 2007;(9):43–6 [Anan'eva LP, Panasyuk EYu, Denisov LN, et al. Pain in the lower back in the practice of a dermatologist, local therapy of Versatis. Spravochnik poliklinicheskogo vracha. 2007;(9):43–6 (In Russ.)].

16. Цветкова ЕС, Денисов ЛН. Новые направления локального лечения остеоартроза коленных суставов. Клиницист. 2014;(2):50–4 [Tsvetkova ES, Denisov LN. New directions for the local treatment of osteoarthritis of the knee. Klinitsist. 2014;(2):50–4 (In Russ.)].

17. Денисов ЛН, Насонова ВА, Тахтай АВ и др. Опыт применения жидкости «Кармолис» для локальной терапии ревматических заболеваний (по данным многоцентрового клинического исследования). Научно-практическая ревматология. 2005;(5):40–3 [Denisov LN, Nasonova VA, Tahtai AV, et al. Experience with Karmolis liquid administration for rheumatic diseases local therapy (data of multicenter clinical examination). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2005;(5):40–3 (In Russ.)].

18. Yano T, Kanetake T, Saita M, et al. Effect of L-menthol and dlcamphor on the penetration and hydrolysis of methylsalicylate in hairless mouse skin. J Pharmacobiology. 1991;14:663–9. doi: 10.1248/bpb1978.14.663

19. Mutschler E. Arztneimittelwirkungen. 1996;(7):195–8.

20. Bauer K, Fromming K, Fuhrer C. Pharmazeutische Technologie. 1997;(4):1913–4.

21. Hansel R, Sticher O, Stemegger E. Pharmakognosie-Phytopharmazie. 1999;(1):29–35.